Andrew Harkin
Associate Professor
Pharmacology
Trinity College Dublin
Ireland
Biography
Andrew Harkin is Associate Professor of Pharmacology in The School of Pharmacy & Pharmaceutical Sciences in Trinity College Dublin and a principle investigator in Trinity College Institute of Neuroscience. He leads a neuropsychopharmacology research group which is focused on bridging neuroscience to the pharmacological treatment of psychiatric and neurological disorders. Current research interests include- - bidirectional nervous system immune interactions, the role of inflammation in the pathogenesis, and potential of anti-inflammatory agents in treating, psychiatric disorders. - targeting the N-methyl-D-aspartic acid (NMDA) receptor and the NMDA-nitric oxide-cGMP intra-neuronal signalling in stress related psychiatric disorders. Professor Harkin's research program is funded by the European Commission (Framework 7), Science Foundation Ireland, the Irish Health Research Board and the Irish Research Council for Science Engineering and Technology, His group collaborates widely with a variety of academic and industrial partners on fundamental and clinical projects.
Research Interest
Addiction and substance abuse; Depression; Emotional, behavioural and cognitive disorders; Imaging Techniques; In vitro testing, trial methods; Neurobiology; Neurochemistry and neuropharmacology; Neuropharmacology; Neuroscience; Psychiatry
Publications
-
Abautret-Daly Ã, Dempsey E, Riestra S, de Francisco-GarcÃa R, Parra-Blanco A, Rodrigo L, Medina C, Connor TJ, Harkin A., Association between psychological measures with inflammatory and disease-related markers of inflammatory bowel disease, International Journal of Psychiatry & Clinical Practise, Mar 29, 2017, p1 - 10
-
Sherwin E, Gigliucci V, Harkin A, Regional specific modulation of neuronal activation associated with nitric oxide synthase inhibitors in an animal model of antidepressant activity, Behavioural Brain Research, 316, 2017, p18 - 28
-
O Farrell K, Fagan E, Connor T.J, Harkin A, Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons, European Journal of Pharmacology, 810, 2017, p163 - 173